Overall, our results provide new evidence that LUCAT1 exerts an oncogenic function, and the LUCAT1/NCL/MYC axis might be a potential prognostic marker and therapeutic target for CRC. The gene discussed is NUCLEOLIN; the disease is colorectal carcinoma.